Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 44 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pediatric Bipolar Disorder Clear all
Completed Phase 4 Interventional

An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.

NCT00391261
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar Disorder, Autism Spectrum Disorders
Interventions
Metformin
Drug
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
10 Years to 18 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Medford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 24, 2010 · Synced Jul 22, 2026, 10:58 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

White Matter in Pediatric Bipolar Disorder: A DTI Study

NCT00391235
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Not listed
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
6 Years to 13 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Medford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 5, 2010 · Synced Jul 22, 2026, 10:58 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children

NCT01050582
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Autistic Disorder, Conduct and Other Disruptive Behavior Disorders
Interventions
Risperidone, Other atypical antipsychotic drugs
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
8 Years to 16 Years
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
13
States / cities
San Francisco, California • Aurora, Colorado • Altamonte Springs, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2012 · Synced Jul 22, 2026, 10:58 AM EDT
Completed Phase 2 Interventional

Lithium for the Treatment of Pediatric Mania

NCT00442039
View directory record Official record
Conditions
Bipolar I Disorder Without Psychotic Symptoms
Interventions
Lithium Carbonate, Placebo
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
7 Years to 17 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Jul 22, 2026, 10:58 AM EDT
Completed No phase listed Observational

Pediatric Bipolar Disorder Study at UCLA

NCT00961935
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
7 Years to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2016 · Synced Jul 22, 2026, 10:58 AM EDT
Recruiting Phase 1 Interventional

Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder

NCT05025605
View directory record Official record
Conditions
Schizophrenia, Schizo-Affective Disorder, Schizophreniform; Schizophrenic, Bipolar Disorder I, Bipolar Disorder II
Interventions
BXCL501 80 Micrograms, Placebo Film, BXCL501 120 Micrograms, BXCL501 60 Micrograms
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
10 Years to 17 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
Anaheim, California • Hialeah, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 22, 2026, 10:58 AM EDT
Withdrawn Phase 4 Interventional

Open-Label Study of Latuda for the Treatment of Mania in Children and Adolescents 6-17 Years Old

NCT01932541
View directory record Official record
Conditions
Mania, Bipolar I, Bipolar II, Bipolar Spectrum Disorder, Bipolar Disorder
Interventions
Latuda (Lurasidone)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Jul 22, 2026, 10:58 AM EDT
Recruiting No phase listed Observational

Studies of Brain Function and Course of Illness in Pediatric Bipolar Disorder

NCT00025935
View directory record Official record
Conditions
Mood Disorder
Interventions
Lithium
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
7 Years to 60 Years
Enrollment
2,350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 22, 2026, 10:58 AM EDT
Terminated Phase 4 Interventional Results available

Omega-3 Fatty Acid Adjunctive to Open-Label Aripiprazole for the Treatment of Bipolar Disorder in Children and Adolescents

NCT00592683
View directory record Official record
Conditions
Pediatric Bipolar Disorder
Interventions
Aripiprazole, fish oil, Placebo
Drug · Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 5, 2012 · Synced Jul 22, 2026, 10:58 AM EDT
Completed Phase 3 Interventional

Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder

NCT04578756
View directory record Official record
Conditions
Schizophrenia, Bipolar I Disorder, Autism Spectrum Disorder (ASD)
Interventions
Cariprazine Flexible Dose
Drug
Lead sponsor
AbbVie
Industry
Eligibility
5 Years to 17 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
40
States / cities
Dothan, Alabama • Bentonville, Arkansas • Anaheim, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Jul 22, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Results available

Risperidone and Divalproex Sodium With MRI Assessment in Pediatric Bipolar

NCT00176202
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Divalproex Sodium, risperidone
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
10 Years to 20 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
3
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Jul 22, 2026, 10:58 AM EDT
Terminated Phase 2 Interventional Results available

Double-Blind Placebo-Controlled Trial of Riluzole in Pediatric Bipolar Disorder

NCT00805493
View directory record Official record
Conditions
Bipolar Disorder, Anxiety Disorders, Bipolar Affective Disorder, Bipolar Depression
Interventions
Riluzole
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
9 Years to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Jul 22, 2026, 10:58 AM EDT
Completed Phase 3 Interventional

Lithium Versus Divalproex for Treating Pediatric Bipolar Disorder

NCT00221429
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium, sodium divalproex, Placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Years to 18 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Jul 22, 2026, 10:58 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Greater Houston Area Pediatric Bipolar Registry

NCT06665984
View directory record Official record
Conditions
Pediatric Bipolar Disorder
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
6 Years to 17 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2046
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Jul 22, 2026, 10:58 AM EDT
Recruiting Phase 3 Interventional

Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

NCT06229210
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Autism Spectrum Disorder
Interventions
Lumateperone
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
5 Years to 17 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
57
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 22, 2026, 10:58 AM EDT
Terminated Phase 4 Interventional Results available

Fluoxetine for Obsessive-Compulsive Disorder in Children and Adolescents With Bipolar Disorder

NCT00592852
View directory record Official record
Conditions
Pediatric Bipolar Disorder, Pediatric OCD
Interventions
fluoxetine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Jul 22, 2026, 10:58 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Brain Activity Flow Patterns Analysis Using Evoked Response Potentials in Youth With ADHD, Bipolar Disorder, or Autism Spectrum Disorders: A Preliminary Study

NCT01506232
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Autism Spectrum Disorder, Bipolar Disorder
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Jul 22, 2026, 10:58 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Brain Imaging and Computer Games in Children With Either Bipolar Disorder, ADHD, Anxiety or Healthy Controls

NCT01570426
View directory record Official record
Conditions
Bipolar Disorder, Attention Deficit Disorder With Hyperactivity, Attention Deficit Disorder Without Hyperactivity, Generalized Anxiety Disorder, Healthy
Interventions
Not listed
Lead sponsor
Bradley Hospital
Other
Eligibility
7 Years to 17 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2018
U.S. locations
1
States / cities
East Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Jul 22, 2026, 10:58 AM EDT
Recruiting Phase 3 Interventional

Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder

NCT05303064
View directory record Official record
Conditions
Schizophrenia, Bipolar I Disorder
Interventions
OLZ/SAM, Olanzapine
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
26
States / cities
Dothan, Alabama • Little Rock, Arkansas • Encino, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jul 22, 2026, 10:58 AM EDT
Completed Phase 1 Interventional

Phase 1 Study of OLZ/SAM in Pediatric Subjects With Bipolar I Disorder

NCT04987658
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
OLZ/SAM
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
10 Years to 12 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Decatur, Georgia • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Jul 22, 2026, 10:58 AM EDT
Terminated Phase 4 Interventional Results available

Invega (Paliperidone) for the Treatment of Mania in Children and Adolescents Ages 6-17 With Bipolar Disorder

NCT00592358
View directory record Official record
Conditions
Pediatric Bipolar Disorder
Interventions
paliperidone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 3, 2012 · Synced Jul 22, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Results available

Pediatric Open-Label Extension Study

NCT01914393
View directory record Official record
Conditions
Schizophrenia, Autism, Bipolar Depression
Interventions
Lurasidone 20, 40, 60, 80 mg, flexibly dosed
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
35
States / cities
Dothan, Alabama • Downey, California • San Francisco, California + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Jul 22, 2026, 10:58 AM EDT
Completed Phase 4 Interventional

Safety And Efficacy Study Of Depakote ER To Treat Pediatric Bipolar Disorder

NCT00199966
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Divalproex sodium extended release
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
6 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 6, 2008 · Synced Jul 22, 2026, 10:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cognitive De-Biasing and the Assessment of Pediatric Bipolar Disorder

NCT01799291
View directory record Official record
Conditions
Decision Making, Bipolar Disorder
Interventions
Decision Making Tutorial
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Not listed
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Jul 22, 2026, 10:58 AM EDT